ArticleCureus2024
Exceptional Response to Pembrolizumab Following Durvalumab Failure in a Patient With Microsatellite Instability-High Cholangiocarcinoma.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Typically, patients with advanced cholangiocarcinoma have a poor prognosis because of the limited effective chemotherapy options available. Studies on genotype-directed therapies for cholangiocarcinoma are increasing. However, limited clinical data are currently available for evaluating the efficacy of molecular-targeted therapies. Herein, we report the case of an 83-year-old man diagnosed with microsatellite instability-high (MSI-H) cholangiocarcinoma. MSI-H was detected using comprehensive genomic profiling after resistance to chemotherapy with durvalumab, an anti-programmed death ligand-1 (anti-PD-L1) antibody. Subsequently, the patient received pembrolizumab, a humanized IgG4 monoclonal antibody that targets anti-programmed cell death protein-1 (anti-PD-1). A CT scan after four cycles of pembrolizumab revealed marked shrinkage of the primary tumor. He experienced grade 2 cutaneous immune-related adverse events, but these events improved with topical steroid treatment. The patient is currently being treated with pembrolizumab for at least 10 months and has not exhibited any tumor (A1) progression. To the best of our knowledge, this is the first report on the efficacy of treatment with an anti-PD-1 antibody in a patient with MSI-H cholangiocarcinoma after the failure of the anti-PD-L1 antibody treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.